NEWS

Media

Stay informed on our innovations, product developments, and industry impact through featured media coverage.

22 April 2022

FDA Accepts Resubmitted BLA for Cosmetic Therapy

22 April 2022

FDA Accepts Revance Resubmission for Frown Line Therapy

22 April 2022

Will A Biotech Rival Finally Shake Up Abbvie’s $2B Botox Cosmetic Franchise? Revance Will Find Out Soon

22 April 2022

Revance Set For September FDA Decision on Botox Rival

22 April 2022

FDA Accepts Revance Resubmission for Frown Line Treatment

22 April 2022

FDA Accepts BLA Resubmission for DAXI Injections

21 April 2022

Revance Therapeutics (RVNC) Announces FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Injection for Glabellar Lines)

21 April 2022

Revance Receives FDA Acceptance of BLA Resubmission for DaxiboutlinumtoxinA for Glabellar Lines

21 April 2022

FDA Accepts Revance Application for Its Injection To Treat Frown Lines

18 April 2022

How Beauty Innovations Are Approved Here and Abroad – Plus the Global Game Changers Doctors are Buzzing About

15 April 2022

What’s The Deal With DAXI, The Neuromodulator Everyone’s Talking About

08 April 2022

Nashville Post: 2022 NAIOP award winners announced